Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. ZYBT
ZYBT logo

ZYBT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.781
Open
0.781
VWAP
0.78
Vol
7.00
Mkt Cap
37.01M
Low
0.781
Amount
5.47
EV/EBITDA(TTM)
--
Total Shares
47.39M
EV
51.57M
EV/OCF(TTM)
--
P/S(TTM)
--
Zhengye Biotechnology Holding Ltd is a company mainly engaged in the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. The Company markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The Company owns about 44 veterinary vaccines in its product portfolio, which cover veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The Company also engages in vaccines for treating livestock. The Company mainly conducts its business in the domestic market. The Company mainly conducts its business in the domestic and overseas market.
Show More

Events Timeline

(ET)
2026-02-10
08:50:00
Zhengye Biotechnology Chairman's Letter to Shareholders Outlines Vision for 2026
select
2025-01-07 (ET)
2025-01-07
09:49:27
Zhengye Biotechnology opens at $3.77, IPO priced at $4.00
select

News

Newsfilter
8.5
02-10Newsfilter
Zhengye Biotechnology Highlights 2025 Achievements and 2026 Strategic Outlook
  • R&D Innovation and Patent Expansion: In 2025, Zhengye secured four new patent grants and filed ten new applications, enhancing its innovation pipeline, which is expected to boost the company's competitiveness in the veterinary drug market.
  • International Market Expansion: The company completed vaccine registration submissions for Egypt and Pakistan in 2025, with approvals anticipated in the first half of 2026, thereby expanding its international market share and enhancing global influence.
  • Production Capability Upgrade: By upgrading its bacterial inactivated vaccine production line to include bacterial subunit vaccine capabilities, Zhengye lays the foundation for future product diversification, which is expected to improve production efficiency and product quality.
  • Deepening Strategic Customer Relationships: The company plans to implement project-based customer development to further integrate resources and channels, aiming to strengthen long-term partnerships with 130 large-scale breeding enterprises, thereby driving sales growth.
Benzinga
2.0
2025-09-24Benzinga
Major Stocks Including Freeport-McMoRan, Harmony Biosciences, and Cohu Decline on Wednesday
  • U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones index dropping over 150 points, influenced by significant losses in various companies, particularly Freeport-McMoRan, which fell 16.4% after issuing disappointing sales guidance and reporting fatalities at its mine.

  • Notable Stock Declines: Other companies also experienced substantial losses, including Zhengye Biotechnology (-28.2%), Harmony Biosciences (-14.6%), and Cohu, Inc. (-12.7%), with Harmony's decline attributed to unmet clinical trial expectations and a lowered price target from Needham.

Benzinga
4.5
2025-09-24Benzinga
Nasdaq Declines by More Than 100 Points; US Crude Oil Inventories Decrease
  • U.S. Stock Market Performance: U.S. stocks declined, with the Dow down 0.35%, Nasdaq falling 0.47%, and S&P 500 dropping 0.40%. Energy shares rose by 1.9%, while materials stocks fell by 1.5%.

  • Significant Stock Movements: uniQure N.V. shares surged 235% after securing a $175 million loan, while SHF Holdings, Inc. rose 120% following a $150 million stock purchase agreement. Conversely, WORK Medical Technology Group's shares plummeted 88%.

  • Commodity and Economic Updates: Crude oil inventories decreased by 0.607 million barrels, contrary to expectations of an increase. New single-family home sales in the U.S. rose by 20.5%, while building permits fell by 2.3%.

  • Global Market Trends: European shares were mostly higher, with the eurozone's STOXX 600 slightly up, while Asian markets closed mostly higher, led by Japan's Nikkei 225 and Hong Kong's Hang Seng.

Benzinga
9.5
2025-09-12Benzinga
RH Reports Disappointing Results, Alongside Frequency Electronics, Tronox, and Other Major Stocks Declining in Friday's Pre-Market Trading
  • U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures dropping approximately 100 points on Friday morning.

  • RH Earnings Report: RH's shares fell 11.5% in pre-market trading after the company reported second-quarter earnings of $2.93 per share, missing the analyst estimate of $3.20, and revenue of $899.15 million, below the expected $904.64 million.

  • Other Stocks Declining: Several other companies also experienced significant declines in pre-market trading, including Rent the Runway (down 27.1%), Frequency Electronics (down 11%), and Zhengye Biotechnology (down 9.3%).

  • Analyst Downgrades: Tronox Holdings saw a 5.7% drop after Mizuho analyst John Roberts downgraded the stock from Neutral to Underperform, setting a price target of $4.

Benzinga
2.0
2025-09-12Benzinga
Adobe Shares Rise Over 4%; Check Out 20 Stocks Making Moves in Premarket Trading
  • Adobe's Strong Performance: Adobe Inc. shares rose 4.4% in pre-market trading after reporting better-than-expected Q3 earnings of $5.31 per share and revenue of $5.99 billion, along with an improved fiscal 2025 outlook.

  • Notable Gainers: Several stocks saw significant pre-market gains, including HCW Biologics (up 94.3%), Huize Holding (up 61.5%), and Millennium Group (up 46.2%), following positive announcements and financial results.

  • Major Losers: Next Technology Holding experienced a sharp decline of 50.6% due to a reverse stock split, while Rent the Runway fell 27.1% after disappointing Q2 earnings.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with notable movements in both directions following recent earnings reports and company announcements.

Benzinga
2.0
2025-08-22Benzinga
Intuit, Workday, and Other Major Stocks Decline in Pre-Market Trading on Friday
  • U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 100 points on Friday.

  • Intuit Inc Performance: Intuit Inc's shares fell 5.5% in pre-market trading despite reporting fourth-quarter revenue of $3.83 billion and adjusted earnings of $2.75 per share, both exceeding analyst expectations.

  • Future Revenue Projections: The company anticipates fiscal year 2026 revenue between $21 billion to $21.19 billion, significantly higher than the estimated $18.75 billion, along with expected adjusted earnings surpassing estimates.

  • Other Stocks Declining: Several other stocks also saw declines in pre-market trading, including ETHZilla Corporation down 12.3%, Blaize Holdings down 8.2%, and Workday Inc down 4.1% following its second-quarter results announcement.

Valuation Metrics

The current forward P/E ratio for Zhengye Biotechnology Holding Ltd (ZYBT.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Zhengye Biotechnology Holding Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding ZYBT

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Zhengye Biotechnology Holding Ltd (ZYBT) stock price today?

The current price of ZYBT is 0.781 USD — it has increased 0

What is Zhengye Biotechnology Holding Ltd (ZYBT)'s business?

Zhengye Biotechnology Holding Ltd is a company mainly engaged in the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. The Company markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The Company owns about 44 veterinary vaccines in its product portfolio, which cover veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The Company also engages in vaccines for treating livestock. The Company mainly conducts its business in the domestic market. The Company mainly conducts its business in the domestic and overseas market.

What is the price predicton of ZYBT Stock?

Wall Street analysts forecast ZYBT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYBT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Zhengye Biotechnology Holding Ltd (ZYBT)'s revenue for the last quarter?

Zhengye Biotechnology Holding Ltd revenue for the last quarter amounts to 31.10 USD, decreased -44.52

What is Zhengye Biotechnology Holding Ltd (ZYBT)'s earnings per share (EPS) for the last quarter?

Zhengye Biotechnology Holding Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Zhengye Biotechnology Holding Ltd (ZYBT). have?

Zhengye Biotechnology Holding Ltd (ZYBT) has 277 emplpoyees as of March 11 2026.

What is Zhengye Biotechnology Holding Ltd (ZYBT) market cap?

Today ZYBT has the market capitalization of 37.01M USD.